"VAR","Variable","UNIT","Measure","COU","Country","YEA","Year","Value","Flag Codes","Flags"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",295.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",304,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",295.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",353.2,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",348.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",350,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",436.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",406.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",406,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",414.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",445.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",472.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",353.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",365.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",381,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",389.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",408.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",424.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",442.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",458.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",474.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",498,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",522.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",548,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",645.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",652.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",650.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",661.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",663.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",686.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",705.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",741.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",762.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",857.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",909.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",943.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1085.9,"E","Estimated value"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",562.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",572.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",585.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",608.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",650.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",672.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",684.3,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",685.6,"E; D","Estimated value; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",731.7,"E; D","Estimated value; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",778,"E; D","Estimated value; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",819.3,"E; D","Estimated value; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",568.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",577.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",599.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",593,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",606.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",618.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",656.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",699,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",745.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",789.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",658.5,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",694.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",502.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",493.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",483.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",494.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",517.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",527.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",545.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",579.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",608,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",636.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",661.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",661.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",389.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",398.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",399.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",408.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",422.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",442.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",472.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",486.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",531.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",574.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",591.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",622.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2010","2010",497.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",503.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2012","2012",492.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2013","2013",502,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",451.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",469.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",480.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",504.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",539,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",556.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",582.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",604.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",725.4,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",774.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",815.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",870.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",394,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",415.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",356.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",347.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",346.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",357.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",385,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",370.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",368.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",383.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",393.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",378,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",382.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",591.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",605,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",552.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",586.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",522.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",519.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",540.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",558.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",607,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",663,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",741.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",808.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",529.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",513.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",540.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",522.4,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",501.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",521.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",549.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",556.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",587.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",605.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",619.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",655.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",433.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",428.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",437.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",442.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",504.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",536.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",541.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",543.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",582.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",601.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",622.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",680.4,"E","Estimated value"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",473.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",508.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",524.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",534.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",502.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",513.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",494.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",504.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",524.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",721.6,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",717,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",716.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",487.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",516.8,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",506.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",514.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",535,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",562.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",577.3,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",601.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",655.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",700,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",749,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",785.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",432.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",436.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",438.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",433.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",423.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",421.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",434.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",426.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",428.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",436.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",430.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",485.1,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",527.5,"D; P","Difference in methodology; Provisional value"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",151.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",196.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",367.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",373.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",333.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",320.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",317.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2015","2015",325.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2016","2016",334.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2017","2017",340.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2018","2018",345.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2019","2019",358.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2020","2020",373.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2021","2021",360.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",115,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",125.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",140.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",143.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",147.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",145,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",157.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",183.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",183.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",211.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",229.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",238.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",257.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",399.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",404.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",414.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",420.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",442.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",441.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",471.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",518,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",540.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",552,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",559,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",652.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",618,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",491.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",447.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",410.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",394.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",398.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",411.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",428.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",430.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",447.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",485.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",489.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",496.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",559.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",412.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",412.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",404.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",462.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",500.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",519.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",575.7,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",556.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",568.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",613,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",585.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",615.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",391,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",370.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",340.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",339.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",367.1,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",369.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",396.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",410.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",642.4,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",692.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",706.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",741.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",810.9,"P","Provisional value"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",426,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",440.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",438.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",440.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",446.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",467.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",483.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",490.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",530.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",564.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",584.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",593,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",638,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",500.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",522.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",548.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",558.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",565.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",604.2,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",633.9,"B; D","Break; Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",649.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",658,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",678.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",696.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",738.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",815.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",231.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",197.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",176.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",175.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",184.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",201.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",222.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",228.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",241.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",273.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",276.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",274.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2010","2010",298.5,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2011","2011",290.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",308.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",327.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",354.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",392.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",410.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",431.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",447.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",134.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",196.4,"B","Break"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",206.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",235,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",236.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",259.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",280.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",282.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",309.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",328.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",330.3,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",328.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",324.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",284.6,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",301,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",321.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",335.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",360.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",375,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",417.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",427.1,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",456.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",483.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",515,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",565.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",568.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",363,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",367,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",364,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",370.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",354.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",363.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",391.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",411,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",439,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",470.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",493.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",516.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",584.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",37,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",36.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",34.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",41.8,"B; D","Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",39.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",38.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",39.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",39.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",38.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",37.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",40,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",43.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",39,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",39,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",39.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",40.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",42,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",43,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",43.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",44.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",46.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",51.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",55.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",57.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",68.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",70.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",70.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",72.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",70.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",72.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",76.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",79.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",79.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",87.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",91.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",94,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",105.7,"E","Estimated value"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",74.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",75.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",77.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",85.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",87.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",91.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",95.9,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",100.1,"E; D","Estimated value; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",113,"E; D","Estimated value; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",126.1,"E; D","Estimated value; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",142.2,"E; D","Estimated value; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",62.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",64.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",69,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",69.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",74.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",75.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",82.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",87.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",92.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",97.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",83,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",87,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",41.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",40.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",42,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",44.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",50.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",54.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",58.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",63.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",70.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",73.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",78.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",47.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",50,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",51.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",53.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",56.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",58.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",62.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",63.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",73,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",53.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",56.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",58.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",61.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",64.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",66.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",66.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",71.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",78.3,"B; D","Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",83,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",87,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",91.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",106.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",93.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",89.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",91,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",95.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",90.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",118.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",123,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",132.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",141.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",150.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",163.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",147.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",50.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",55.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",51.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",49,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",50.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",51.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",56.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",59.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",62.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",75.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",73.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",75,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",49,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",43.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",38.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",48.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",41.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",42.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",46.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",45.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",49.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",57.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",66.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",76.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",68,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",62.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",65.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",62.2,"B; D","Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",54.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",54.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",55.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",56.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",60.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",65.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",50.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",53.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",55.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",57.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",59.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",63.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",65.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",68.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",74,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",74.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",80,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",89.4,"E","Estimated value"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",40.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",41.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",43,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",41.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",36.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",29.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",30.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",28.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",42.7,"B; D","Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",43.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",42.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",78.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",79,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",74.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",76.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",79.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",84.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",87.7,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",92.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",100.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",107.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",117.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",123.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",65.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",65.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",66.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",72.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",76.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",77.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",78.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",81.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",80.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",85.6,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",87.5,"D; P","Difference in methodology; Provisional value"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",47.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",49,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",46.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",48.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",47.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",10.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",11.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",12.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",13.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",13.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",16.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",23.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",40.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",41.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",41.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",43.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",48.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",53.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",57.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",60.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",65.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",80.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",87.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",77.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",69.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",63,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",64.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",67.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",72.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",78.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",80.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",87.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",97.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",103.9,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",112,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",131.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",43,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",44,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",41.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",47.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",52,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",57.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",68,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",66.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",68.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",74.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",76.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",82.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",52.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",53.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",51.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",53.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",60.2,"B; D","Break; Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",63.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",70.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",75.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",88.4,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",96.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",100.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",109.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",122.8,"P","Provisional value"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",44.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",44,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",45.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",45.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",45.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",47.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",50.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",51.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",54.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",60.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",63.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",67.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",75.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",76.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",76.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",78.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",80.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",82.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",87,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",91.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",93,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",92.2,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",95.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",100.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",107.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",119.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",32.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",25.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",26,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",27.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",30.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",34,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",37.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",39.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",44.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",50.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",51.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",31,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",31.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",34.1,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",37.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",39.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",41,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",43.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",24.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",30.7,"B","Break"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",33.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",35.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",39.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",45.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",50,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",52.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",53.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",62.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",62.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",63.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",57.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",34.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",35.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",39,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",41.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",44.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",46.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",49.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",50.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",53.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",55.6,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",59.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",60,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",66,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42.4,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",43.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",41.5,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",41,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",41.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",43,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",47.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",49,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",52.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",58.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",62.8,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",64.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",75.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.2,"E","Estimated value"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",0,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.2,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0,"B; D","Break; Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.9,"E","Estimated value"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",2.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",2.2,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.6,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.6,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.7,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.7,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.7,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.7,"D; P","Difference in methodology; Provisional value"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.9,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.9,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.9,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",1,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.9,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.3,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.6,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.5,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",1.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.7,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.3,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.5,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.5,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.6,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.6,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.9,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",19,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.6,"B; D","Break; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",14,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",13.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",12.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",11.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",10.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",13.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",12.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",12.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",11.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",11.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",4.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",19.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",19.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",15.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",16.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",18.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",17.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",18,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",19.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",19.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",18.7,"E","Estimated value"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",30,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",27.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",26,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",23.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",22.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",19.1,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",18,"E; D","Estimated value; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",19,"E; D","Estimated value; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",18.9,"E; D","Estimated value; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",18.3,"E; D","Estimated value; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",9.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",9.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",10.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",9.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",8.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",6.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",7.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",6.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",5.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",6.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",5.5,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",5.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",7.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",7.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",7.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",5.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",13.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.3,"B; D","Break; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",10.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",33.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",29.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",26,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",24.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",23.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",26.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",24.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",24.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",26.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",21.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",14.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",14.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",9.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",9.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",13.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",12.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",11.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",12.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",13.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",13.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",13.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",14.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",28.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",28.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",25.3,"B; D","Break; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",13.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",21.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",23.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",20.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",20.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",19.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",19.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",19.8,"E","Estimated value"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",17.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.4,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",17.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",17.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",18.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",20,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",20.5,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",23.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",24.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",27.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",19.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",19.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",19.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",15.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",16.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",15.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",15,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",14.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",13.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",12.5,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.8,"D; P","Difference in methodology; Provisional value"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",13.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",8.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",6.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",6.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",6.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",6.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",6.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",28.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",18.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",10.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",10.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",11,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",12.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",12.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",12.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",13.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",3.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",3.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.8,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",4.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",4.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",19.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",16.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",13.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",13.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",13.7,"B; D","Break; Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",13.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",14.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",14.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",15.2,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",16,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",17,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",18.6,"P","Provisional value"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",6.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",6.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",5.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",9.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",5.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",5.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.5,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",3.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",4.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",4.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",3.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",3.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",4.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",5.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",5.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",5.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",5.3,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.5,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",15.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",14,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",10.8,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",8.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",8.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",8.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",8.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",13.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",14.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",17.7,"B; D","Break; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",17.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",19.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",20.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",20.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",23.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",26.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",16.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",17,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",18.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",19.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",22.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",24.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",26.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",29.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",32.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",33.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",15.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",16.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",17,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",18.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",19.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",19.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",22.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",30.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",39.9,"E","Estimated value"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",28.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",31.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",38.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",49.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",53.7,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",57.6,"E; D","Estimated value; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",65.9,"E; D","Estimated value; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",74.7,"E; D","Estimated value; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",88.2,"E; D","Estimated value; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",25.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",26.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",30,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",30.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",34.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",37.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",41.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",45.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",48.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",51.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",53.5,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",56,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",21.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",24.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",25.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",26.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",28.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",34.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",37.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",39.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",28.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",30.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",32.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",35.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",35.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",36.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",39,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",40.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",43.2,"B; D","Break; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",46.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",49.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",52.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",37.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",35,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",37.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",41.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",46,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",43.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",62.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",75.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",73.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",89.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",24.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",27,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",30.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",31.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",34.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",40.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",45,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",48.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",47.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",50.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",14.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",15,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",15.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",16.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",17.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",17.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",21.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",26.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",34.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",43.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",21.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.9,"B; D","Break; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",21.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",24.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",25.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",27.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",28.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",31.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",33.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",16.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",17.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",18.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",18,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",19.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",21.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",21.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",23,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",25.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",30.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",36.9,"E","Estimated value"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",13.7,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",15.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",19.2,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",21.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",24.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",26.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",30.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",32.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",20.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",23.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",26.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",30.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",33.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",35.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",37.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",39,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",41.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",43.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.3,"D; P","Difference in methodology; Provisional value"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",18.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",20.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",6.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",6.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",6.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",8.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",10.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",11.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",16.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",11.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",12.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",13.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",13.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",14.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",15.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",21.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",26.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",37.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",45.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",31.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",33.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",35.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",37.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",39.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",43.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",47.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",49.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",54.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",62.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",69,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",74.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",90.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",14.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",15.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",14.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",17.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",23.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",24.7,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",23.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",24.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",26.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",28.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",29,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",23.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",26.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",32.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.9,"B; D","Break; Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",41.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",46.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",49.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",53.9,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",59.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",67.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",76.9,"P","Provisional value"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",15.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",15.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",16.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",16.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",16.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",17.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",20.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",23.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",26.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",29.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",38.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",9.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",10.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",12.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",17.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",20.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",19.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.8,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",6.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",12.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",14.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",22.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",25.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",28.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",16.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",17.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",22.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",23.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",24.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",25.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",27.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",29.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",32.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",33.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",38.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",23.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",23.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",25.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",26.7,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",28.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",31.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",34.3,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",36.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",45.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",12.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",11.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",14.4,"B; D","Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",16,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",19,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",22.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",23.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",25.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",21.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",20.9,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",24,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",28.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",32.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",35.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",41.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",45.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",49.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",53.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",57.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",60.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",49.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",48.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",49.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",54.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",55.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",63.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",67.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",69.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",79.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",88.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",95.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",107.4,"E","Estimated value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",20,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",21.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",24.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",26.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",27.9,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",29,"E; D","Estimated value; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",31.5,"E; D","Estimated value; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",33.2,"E; D","Estimated value; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33.1,"E; D","Estimated value; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",36.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",38.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",44.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",46.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",51.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",54.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",59.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",65.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",71.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",75,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",71.4,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",79.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",29.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",29,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",31.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",34,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",38.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",41.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",45.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",55.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",58,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",62,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",65.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",27.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",28.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",31.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",32.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",35.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",40.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",45.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",50.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",58,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",62.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",64.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",38.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",25.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",25.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",27.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",37.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",40.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",45.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",51.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",60.3,"B; D","Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",67.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",75.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",86.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",80.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",73.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",67.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",67,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",73.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",68.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",268.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",165.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",179.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",137.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",131.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",142.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",146.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",31.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",32.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",31.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",31.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",34.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",37.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",41,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",37.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",34.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",39.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",43.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",44.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",46.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",31.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",29.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",30.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",35.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",33.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",40.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",37.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",48.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",54.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",60.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",23.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",24.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",23.9,"B; D","Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",23.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",25,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",32.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",33.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",35.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",37.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",39.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",39.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",38.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",44.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",47.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",50,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",50.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",55.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",59.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",61.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",66,"E","Estimated value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",31.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",33.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",38.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",38.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",34.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",35.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",31.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",31.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",35.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",52,"B; D","Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",49.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",48.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",39.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",41.4,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",42.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",44.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",47.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",45.5,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",47,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",52.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",55.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",60.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",63,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",21.9,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",22.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",24.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",26.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",28.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",32.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",34.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",36.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",39.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",41,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",45.5,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",46.4,"D; P","Difference in methodology; Provisional value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",4.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",2.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",2.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",2.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",2.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",1.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",1.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",1.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",17.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",17.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",19.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",19.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",6.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",7.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",12.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",9.9,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",11.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",11.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",13.9,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",17,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",26.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",28.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",34.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",35.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",40.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",49.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",52.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",52,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",57,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",52.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",18.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",13.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",15,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",18.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",23.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",29.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",32.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",38.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",45,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",45.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",48.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",53.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",37.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",35.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",39.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",44.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",51,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",55.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",66.1,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",68,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",74.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",76.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",71.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",60.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",18.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.9,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",16.7,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",19.3,"B; D","Break; Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",21.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",24.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",27.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",55.4,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",60.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",62.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",68.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",73.9,"P","Provisional value"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",37.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",38.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",38.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",38.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",40.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",48.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",51.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",56.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",60.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",62,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",66,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",18.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",18.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",20.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",23.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",25.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",27.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",31.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",35.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",38.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",40.2,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",43,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",48.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",10.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",10.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",13,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",16,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",17.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",20.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",21.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",21.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",13,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",14.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",16.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",20,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",22.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",26.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",29.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.2,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",12.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",13.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",13.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",12.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",15.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",17.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",17.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",23.3,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",20.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",19.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",20.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",25.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",30.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",41.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",50,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",53.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",58,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",59.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",60.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",19.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",19.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",23.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",25.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",28.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",33.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",39.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",46.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",52.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",62.8,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",68.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",82.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",83.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",72.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",75.2,"B; D","Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",64.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",56.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",53,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",49.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",49.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",49.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",52.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",70.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",71.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",70.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",64.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",63.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",61.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",63,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",63.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",61.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",59.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",58.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",56.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",98.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",96.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",92,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",87,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",80.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",77.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",77.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",74.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",67,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",69.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",69,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",66.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",71.8,"E","Estimated value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",107.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",95.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",91.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",87.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",90.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",90.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",75.7,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",68.1,"E; D","Estimated value; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",70.9,"E; D","Estimated value; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",71.7,"E; D","Estimated value; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",73,"E; D","Estimated value; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",90.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",90.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",90.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",86.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",79.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",74.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",76.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",78.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",79.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",82.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",73.8,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",74.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",40.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",34.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",30.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",27.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",27.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",27.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",26.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",27.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",25,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",30.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",31.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",27.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",40.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",36.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",35.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",36.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",38.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",40.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",43.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",36.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",32.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",30.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",28.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",74,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",75.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",71.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",71.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",70.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",67.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",70.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",72,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",74.5,"B; D","Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",77.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",79.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",80.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",177.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",166,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",158.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",147.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",143.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",134.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",148.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",141.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",140.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",144.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",139.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",143.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",117.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",102.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",102.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",85,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",77.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",71,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",69.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",71.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",69.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",68.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",68.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",70.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",64.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",64.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",45.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",45.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",42.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",40.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",39.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",36.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",36.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",38.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",40.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",42.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",45.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",47.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",102.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",89.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",89.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",76.9,"B; D","Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",61.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",57.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",57.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",55.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",54.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",51.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",52.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",100.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",89.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",84.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",80.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",80.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",85.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",85,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",78.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",81.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",85.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",86.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",93.1,"E","Estimated value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",98,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",98.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",97.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",97.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",88.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",82.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",75.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",70.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",60.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",75.8,"B; D","Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",72.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",70.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",67.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",69.8,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",66.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",66.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",66.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",69.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",72.9,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",77.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",85.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",89.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",102.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",111.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",93.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",96.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",93.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",86.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",75.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",72.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",66.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",57.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",55.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",54.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",54.4,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",55.9,"D; P","Difference in methodology; Provisional value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",11.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",11.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",10.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",10.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",8.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",9.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",11.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",9.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",8.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",7.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",7.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",5.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",5.8,"E","Estimated value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",63.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",64.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",56.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",53.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",50,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",18.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",20.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",13.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",10.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",9.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",7.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",7.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",6.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",6.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",6.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",9.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",41.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",39.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",36,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",32.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",31,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",29.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",31,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",33.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",34,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",34.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",36.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",33.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",135.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",118.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",105.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",96.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",94.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",91.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",91.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",84,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",88.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",92.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",94.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",103.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",67.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",69.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",60.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",59.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",59.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",58.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",71,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",67.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",65.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",67.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",70.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",71.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",90.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",77.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",68,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",66.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",69.5,"B; D","Break; Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",69.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",74.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",74.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",77.8,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",81.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",82.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",82.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",89.8,"P","Provisional value"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",36.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",36.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",27.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",27.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",27.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",27.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",28.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",28.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",31.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",33.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",32.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",35.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",82.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",84,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",80.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",74.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",73.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",75.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",79.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",78.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",77.1,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",80.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",81.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",89.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",96.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",27.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",16.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",17,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",17.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",19.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",19.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",22.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",24.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",29.8,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",25.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",26.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",28.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",28.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",28.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",28.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",12.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",15.2,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",16.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",17.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",19,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",19.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",21.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",20,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",20.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",24,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",23.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",24.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",51.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",45.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",47.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",46,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",46.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",44.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",44.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",42.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",43.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",44.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",49.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",47.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",93.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",88.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",84.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",82.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",66.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",62.7,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",63.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",64.4,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",64.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",68.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",72.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",71.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",77.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.1,"B; D","Break; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",0.1,"E","Estimated value"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.4,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.3,"E; D","Estimated value; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.4,"E; D","Estimated value; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.3,"E; D","Estimated value; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.3,"E; D","Estimated value; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",0.1,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",0.6,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",0.6,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",0.3,"B; D","Break; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",0.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",0.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.4,"B; D","Break; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.1,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.1,"D; P","Difference in methodology; Provisional value"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.5,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.4,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",0.1,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",0.1,"B; D","Break; Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",0.1,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.1,"P","Provisional value"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",0.2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.2,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.3,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.5,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.5,"B; D","Break; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.5,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",1.6,"E","Estimated value"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",0.6,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",0.5,"E; D","Estimated value; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",0.5,"E; D","Estimated value; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",0.5,"E; D","Estimated value; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",0.5,"E; D","Estimated value; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",1.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",1.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",1.6,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",0.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.4,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",2.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",2.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",2.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",0.8,"B; D","Break; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",1.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",1.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",1.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.3,"E","Estimated value"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.3,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.3,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",0.9,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",0.8,"D; P","Difference in methodology; Provisional value"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.2,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",1.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.2,"B; D","Break; Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",0.8,"P","Provisional value"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",0.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",1.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",0.6,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.2,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",0.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",0.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",0.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",0.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",1.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",2.6,"B; D","Break; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",2.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",2.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",2.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",5.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",5.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",7.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",7.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",7.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",7.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",7.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",1.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",2.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",2.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",2.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",2.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",2.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",2.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",4.4,"E","Estimated value"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",1.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",1.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",2.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",2.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",2.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",2.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",2.4,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",2.5,"E; D","Estimated value; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",2.7,"E; D","Estimated value; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",2.7,"E; D","Estimated value; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.3,"E; D","Estimated value; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",6.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",5.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",5.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",5.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",5.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",5.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",5.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",5.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",5.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",5.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",5.1,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",4.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",5.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",5.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",5.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",5.2,"B; D","Break; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",4.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",5.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",4.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",4.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",4.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",5.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",6.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",6.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",0.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",1.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",1.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",1.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",5.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",5.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",5.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.5,"B; D","Break; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",4.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",4.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",4.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",4.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",5.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",5.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",4.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",4.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",4.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",4.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.6,"E","Estimated value"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.7,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",0.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",0.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",0.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",0.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",1.1,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",1.3,"D; P","Difference in methodology; Provisional value"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",2.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",2.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",2.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",2.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",1.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",1.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",1.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",1.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",4.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",6.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8.4,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",6.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.3,"B; D","Break; Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",1.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",1.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",1.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",1.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",3.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",3.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.4,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",1.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",1.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",1.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",1.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",1.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",1.7,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",3.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",3.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",3.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",3.6,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",3.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",3.4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",3.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1.1,"B; D","Break; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",2.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",2.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",3.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",3.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",4.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",3.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",3.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",3.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",3.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",3.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",3.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",3.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",3.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",3.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.4,"E","Estimated value"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",5.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",5.8,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",5.7,"E; D","Estimated value; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.4,"E; D","Estimated value; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.2,"E; D","Estimated value; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",7.5,"E; D","Estimated value; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",3.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",3.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",3.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",4.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",4.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",4,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",4.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",7.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",7.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",7.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8,"B; D","Break; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",9.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",4.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",4.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",4.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",5.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",4.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",5.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",5.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",5.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",5.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",5.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",4.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",3.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",3.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",3.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",3.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",4.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",5.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",4.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",4.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",4.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",4.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",4.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.4,"B; D","Break; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",3.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",3.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",2.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",3.2,"E","Estimated value"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.6,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",0.5,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",3.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",3.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",3.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.7,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.6,"D; P","Difference in methodology; Provisional value"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",5.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",5.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.9,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",4.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",2.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",3.3,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.3,"B; D","Break; Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.8,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",4.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",4.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",4.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4.3,"P","Provisional value"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",1.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.5,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",0.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",0.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",0.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",1.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",4.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",4.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",4.8,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",5.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",5.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",5.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.5,"B; D","Break; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",4.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",4.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",4.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",4.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",4.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",4.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",4.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",11.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",10.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",10.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",10.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",10.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",9.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",9.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",9.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",8.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.3,"E","Estimated value"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",7.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",7.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",7.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",6.7,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",6.2,"E; D","Estimated value; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",5.9,"E; D","Estimated value; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",5.3,"E; D","Estimated value; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",8.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",8.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",8.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",8.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",8.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",8.1,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",8.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",5.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",5.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",5.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",5.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",5.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",5.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",4.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",4.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",4.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",4.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",10.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",10.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",10.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",10.9,"B; D","Break; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",10.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",10.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",8.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",9.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",9.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",9.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",11.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",13.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",9.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",7.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",7.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",7.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",7.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",7.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",7.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",7.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",7.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",8.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",7.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.3,"B; D","Break; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",6.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",6.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",5.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",5.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",5.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",5.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",5.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",6.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",8.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",9.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.3,"E","Estimated value"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",4.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.6,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",2.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",2.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",2.8,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",2.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",3.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",3.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",7.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",8.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",8.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",7.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",7.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.9,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6.2,"D; P","Difference in methodology; Provisional value"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",7.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",6.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",3.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",3.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",3.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",3.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",3.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",3.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",3.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",3.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",3.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",3.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",3.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",5.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",4.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",4.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",5.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",5.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",5.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",5.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",5.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",6.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",6.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",6.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",6.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",5.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",5.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",5.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",8,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",7.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",7.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",8.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",8.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",8.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",2.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",2.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",2.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",2.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",2.7,"B; D","Break; Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",2.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",2.9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.1,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.7,"P","Provisional value"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",5.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",4.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",4.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",4.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",4.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",4.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",2.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",2.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",3.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",3.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",3.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.8,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",2.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",2.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",2.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",2.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",3.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",7.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",7.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",7.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",7.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",8.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.9,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.1,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",8.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",8.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",9.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",3.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.9,"B; D","Break; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",3.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",3.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",3.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",3.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",4.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",4.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",4.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",6.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",6.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",5.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",5.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",4.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",4.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",4.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",3.7,"E","Estimated value"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",14.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",13.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",12.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",12.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",12.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",12,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",10.6,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",9.2,"E; D","Estimated value; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9,"E; D","Estimated value; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",8.8,"E; D","Estimated value; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",8.6,"E; D","Estimated value; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",5.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",5.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",5.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",5.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",4.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",3.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",3.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",3.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",3.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",3,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",2.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",3.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",3.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",3.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",3.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",3.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",3.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",3.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",2.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",2.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",4.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",4.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",4.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",4.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",4.9,"B; D","Break; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",5.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",5.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",5.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",11.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",9.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",8.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",8.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",7.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",7.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",7.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",7.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",6.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",5.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",5.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",1.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",1.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",5.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",4.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",4.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",4.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",3.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",3.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",3.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",3.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",3.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",4.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",5.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",6.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",6.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",6.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",6.4,"B; D","Break; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",8.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",7.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",6.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",6.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",6.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",7.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",6.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",7,"E","Estimated value"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",12.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",11.6,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",10.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",9.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.9,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",7.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",7.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",4.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",4.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",3.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",2.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",2.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",2.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",2.2,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",2.1,"D; P","Difference in methodology; Provisional value"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",8.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",6.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",5.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",4.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",4.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",4.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",3.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",3.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",3.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",4.1,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",3.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",5.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.7,"B; D","Break; Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.7,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.9,"P","Provisional value"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",3.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",2.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",2.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",1.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",1.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.6,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",1.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",1.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",1.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",1.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",0.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",0.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",0.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",0.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",0.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",3.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",3.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.7,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",2.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.4,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",5.3,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",5.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",5.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",4.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",4.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",4.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",4.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",4.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",17.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",18,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",22.1,"B; D","Break; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",20.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",18.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",16.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",18.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",27.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",28.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",28.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",23.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",22.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",23.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",23.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",21.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",20.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",18.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",25.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",25.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",22.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",21.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",21.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",19.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",22.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",22.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",23,"E","Estimated value"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",28.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",27.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",29.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",29.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",23.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.4,"E; D","Estimated value; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.2,"E; D","Estimated value; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",20.5,"E; D","Estimated value; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",20.8,"E; D","Estimated value; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",27.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",27.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",26.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",25.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",22.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",20.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",21.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",22,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",22,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",23.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",23.7,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",24.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",16.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",12.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",8.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",7.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",32.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",34,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",29.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",25,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",25.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",26.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",27.6,"B; D","Break; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",29.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",30.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",31.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",66.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",62.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",57.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",57.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",54.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",50.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",50.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",47,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",44.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",36.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",38,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",36.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",30.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",28.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",27,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",28.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",28,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",28.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",29.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",30.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",28.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",28.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",12.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",12.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",9.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",9.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",10.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",11.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",12.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",12.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",24.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",22.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",20.5,"B; D","Break; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",13.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",42.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",37,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",34.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",31.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",30.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",31.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",29,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",30,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",31.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",31.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",33.2,"E","Estimated value"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",23.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",25.1,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",24.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",24.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",24.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",25.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.3,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",27.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",30.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",34.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",36.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",33.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",32.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",29.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",25.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",24.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",23.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",21.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",21,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.6,"D; P","Difference in methodology; Provisional value"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",18.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",18.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",15,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",12.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",5.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",4.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",18.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",17.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",9.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",60.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",56.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",50.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",44,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",41.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",38.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",36.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",34.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",33.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",35.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",37.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",41.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",21.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",22.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",19.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",17.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",21.4,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",20.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",21.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",22.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",23.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",23.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",36.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",34.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",29.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",29.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",29.1,"B; D","Break; Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",28.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",29.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",28.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",28.3,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",29.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",29.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",30.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",33.1,"P","Provisional value"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",7.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",4.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",4.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",8.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",12.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",9.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",7.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",7.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",6.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",6.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",6.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",6.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",8.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",7.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",4.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",5.4,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",5.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",6.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",10.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",17.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",18.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",18.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",17.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",17.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",17.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",18,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",19.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",19.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",19.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",42,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",40.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",37.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",35,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",27.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",24.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",23.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",24.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",24.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",26,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",27.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",27.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",30.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",50.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",52,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",43.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",38.5,"B; D","Break; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",30.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",18.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",17.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",17.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",14.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",13.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",13.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",16.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",16.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",15.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",14.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",15.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",34.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",35.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",32.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",24.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",24.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",19.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",18.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",18.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",18.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",21.3,"E","Estimated value"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",42.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",31.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",27.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",28.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",27.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",19.7,"E; D","Estimated value; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",20.5,"E; D","Estimated value; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",21.4,"E; D","Estimated value; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",22.3,"E; D","Estimated value; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",20.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",21.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",23.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",21.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",15.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",14.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",15.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",15.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",15.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",15.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",11.7,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",11.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",7.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",7.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",8.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",9.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",13.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",13.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",6.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",5.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",4.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",10.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",10.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",10.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",9.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",10.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",13,"B; D","Break; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",12.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",67.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",60.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",57.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",52.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",52.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",46.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",54.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",50.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",54.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",56.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",52.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",57.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",47.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",29.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",29.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",18.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",15.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",14.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",14.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",14.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",12.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",12.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",13,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",7.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",8.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",8.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",7.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",6.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",6.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",7.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",7.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",8.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",50,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",38.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",30,"B; D","Break; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",16.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",14.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",14.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",15.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",30.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",25.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",23.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",24.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",23.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",25,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28.5,"E","Estimated value"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",16.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",18.3,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",18.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",20.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",21.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",26.9,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",30,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",44.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",50.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",36.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",40,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",39.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",29.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",27.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",28.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",25.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",19.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",17.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",16.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",20.5,"D; P","Difference in methodology; Provisional value"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",21.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",22.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",17.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",15.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",15.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",5.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",8.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",8.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",8.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",7.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",7.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",9.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",9.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",8.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",9.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",30.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",25.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",26.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",26.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",24.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",26,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",29,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",33.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",8.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",8.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",9.5,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",9.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",10.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",11.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",20.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",20.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",23.2,"B; D","Break; Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",24.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",27.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",29.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",29.1,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",30.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",31.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",31.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",35.4,"P","Provisional value"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",9.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",6.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",5.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",5.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",5.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",6.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",5.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",5.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",6.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",1.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",1.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",1.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",1.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",2.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",2.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",2.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",2.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",2.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",3.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.2,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",5.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",5.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",4.9,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",5.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",5.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",6.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",5.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",5.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",4.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",23.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",21.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",20.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",20.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",11.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",11.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",12.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",12.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",13.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",15.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",15.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",17.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",4.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",4.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",4.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",6.7,"B; D","Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",8.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",10.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",10.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",11.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",6.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",6.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",6.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",25.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",25.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",25.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",24.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",25.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",25.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",24.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",26.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",25.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",27,"E","Estimated value"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",34.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",34.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",35,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",33.2,"E; D","Estimated value; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",32.7,"E; D","Estimated value; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",32.7,"E; D","Estimated value; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",32.1,"E; D","Estimated value; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",34.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",34.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",36,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",33.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",33.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",32.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",32.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",32.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",33.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",34.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",16.2,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",15.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",24.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",22.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",23.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",21.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",19.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",20.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",20.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",21,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",20.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",21,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",20.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",20.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",22.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",21.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",21.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",22.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",22.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",22.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",23.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",23.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",23.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",24.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",22.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",20.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",18.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",13.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",12.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.8,"B; D","Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",13.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",13.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",13.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",26.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",24.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",21.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",21.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",22.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",19.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",24.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",27,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",27.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",29.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",27.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",28.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",24.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",6.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",7.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",8.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",8.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",35.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",33.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",33.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",33.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",29.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",28,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",28.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",27.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",29,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",30.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",21.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",21.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",22.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",21.2,"B; D","Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",19.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",19.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",20.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",18.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",19,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",19.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",20.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",23.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",12.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",13.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",10.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",11.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.1,"E","Estimated value"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",11.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",11.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",13.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",13,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",11.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",11.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",10,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",12,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",12.7,"B; D","Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",13.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",12.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",13,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",15.1,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",14.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",14.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",16,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",17,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",16.6,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",17.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",19.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",20.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",22.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",18,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",18.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",18.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",19.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",20.2,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",19.2,"D; P","Difference in methodology; Provisional value"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",14.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",10.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",10.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",3.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",20.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",20.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",20.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",21.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",21.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",23.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",24.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",25.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",22.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",26.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",25,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",24.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",25.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",25,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",26.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",26.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",26.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",27,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",26.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",16.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",16.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",15.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",18.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",19.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",19.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.8,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",16.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",16.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",16.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",15.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",15.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.7,"B; D","Break; Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",17.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",19.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",20.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",21.2,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",20.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",18.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",22.3,"P","Provisional value"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",20.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",20.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",21.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",20.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",19.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",19.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",19.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",19.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",20.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",33,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",34,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",34.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",34.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",34,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",34.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",33.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",34.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",35.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",10.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",8.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",8.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",8.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",10,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",11.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",12.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",15.3,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",15.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",15.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",15.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",15.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",16.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",15.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",13.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",18.5,"B","Break"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",20.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",21.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",22.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",23.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",24.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",25.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",25.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",25.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",28.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",25.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",15.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",16.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",16.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",16.6,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",16.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",16.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",16.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",16.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",17.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",17.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",16.7,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",20.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",20.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",19.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",19.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",19.5,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",18.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",19.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",20.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",19.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",19.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",16.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.8,"B; D","Break; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",7.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",7.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",7.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",7.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",2.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",2.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",14.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",14.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",12.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",12.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",12.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",12.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",12.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",13.1,"E","Estimated value"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",17.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",18.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",18.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",18.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",18.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",18.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",18.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",17.5,"E; D","Estimated value; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",16.8,"E; D","Estimated value; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",16.2,"E; D","Estimated value; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",15.6,"E; D","Estimated value; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",19.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",19,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",19.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",18.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",17.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",16.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",16.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",16.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",16.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",16.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",6,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",11.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",11.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",11.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",11.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",12.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",12.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",12.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",12.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",11,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",6.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",6.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",6.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",6.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",6.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",6.2,"B; D","Break; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",6.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",6.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",6.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",8.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",8.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",6.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",5.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",6.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",5.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",5.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",6.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",6.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",7.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",7.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",6.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",3.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",3.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",3.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",4.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",20,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",19.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",19.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",15.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",16.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",16.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",9.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",9,"B; D","Break; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",8.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",9.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",8.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",8.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",9.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",3.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",3.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",3.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",3.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",3.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",3.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",2.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",2.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",2.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",2.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",2.9,"E","Estimated value"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",3.6,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.3,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",5.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",6.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",7.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",7.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",8.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",9.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.9,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.5,"D; P","Difference in methodology; Provisional value"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",8.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",5.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",4.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",4.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",2.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",9.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",11.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",9.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",12.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",11.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.5,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",10.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",10.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",10.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",11,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",7.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",7.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",6.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",6.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.9,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",6.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",6.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",6.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",6.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.6,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",4,"P","Provisional value"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",10.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",10.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",10.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",10.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",10.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",10.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",10.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",10.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",10.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",11.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",2.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",2.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",2.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",2.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",3.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",3.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",10.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",13.4,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",15.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",15.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",16.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",19.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",17,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",17.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",18.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",19,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",22.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",18.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",9.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",9.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",8.9,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",8.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",8.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",7.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",7.4,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",7.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",6.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",5.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",5.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",5.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",2.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",4.7,"B; D","Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",4.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",5.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",6.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",6.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",6.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",6.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",7.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",7.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",7.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",7.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",7.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",8.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",9.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",9.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",13.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",13.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",13.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",13.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",13.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",14.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",14.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",15.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",15.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",15,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",16,"E","Estimated value"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",9.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",10.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",11.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",11.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",12.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.9,"E; D","Estimated value; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",13.3,"E; D","Estimated value; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",13.8,"E; D","Estimated value; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",14,"E; D","Estimated value; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",11.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",11.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",12.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",12.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",13,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",12.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",13.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",15,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",15.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",15.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",14.9,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",15,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",11.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",12,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",11.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",10.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",11.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",11.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",11.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",12.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",12.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",13.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",12.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",12.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",8.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",8.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",7.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",8.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",8.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",9.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",9.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",10.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",10.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",10.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",9.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",15,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",15.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",16.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",16.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",17.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",17.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",18,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",18.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",19.4,"B; D","Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",20.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",20.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",21.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",16.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",15.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",19.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",20.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",21.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",24.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",25.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",27.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",22.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",6.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",6.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",6.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",7.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",8.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",8.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",8.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",8.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",7.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",13.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",14.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",14.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",15,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",14.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",17,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",17.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",17.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",11.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",12,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",12.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",13.4,"B; D","Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",13.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",14.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",15.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",15.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",10.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",10.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",10.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",12.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",12.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",12.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",13.5,"E","Estimated value"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",10.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",11.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",12.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",12.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",13.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",11.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",13.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",11.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",19.7,"B; D","Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",19.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",21.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",5.5,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",5.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",5.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",5.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",5.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4.5,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",5.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",6.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",9.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",9.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",10.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",11.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",11.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",11.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",11.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",11.6,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",11.4,"D; P","Difference in methodology; Provisional value"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",12.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",12.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",9.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",4.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",4.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",3.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",10.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",11.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",12.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",11.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",3.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",3.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",3.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",4.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",4.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",4.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",4.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",4.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",4.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",5.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",7.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",6.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",7.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",8.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",9.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",9.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",10,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",9.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",9.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",10.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",9.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",9.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",7.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",6.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",7.3,"B; D","Break; Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",7.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",7.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",13.2,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",14.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",13.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",13.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",15.1,"P","Provisional value"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",10.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",11.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",11.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",11.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",11.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",11.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",11.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",12.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",12.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",12.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",12,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",12.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",6.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",6.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",7.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",7.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",8.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",8.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",9.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",8.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",8.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",9.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",8.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",9.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",3.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",3.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",4.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",7.6,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",10.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",13.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",13.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",11.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",9.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",3.1,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",3.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",6.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",8.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",8.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",3.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",5.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",5.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",6.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",6.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",6.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",7.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",7.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",7.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",6.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",7.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",7.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",7.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7.6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",8.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",9.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",9.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",9.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",10.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",11.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",23.6,"B; D","Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",23.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",23.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",97.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",69.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",48.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",36.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",30.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",27.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",23.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",23.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",25.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",27.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",35.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",42.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",38.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",39,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",36.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",32.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",28.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",62.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",63.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",63.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",64.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",64.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",75.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",71.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",76.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",72.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",81.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",75.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",74.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",81.7,"E","Estimated value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",34.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",38.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",54.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",52.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",52.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",54.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",49,"E; D","Estimated value; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",42.3,"E; D","Estimated value; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",41.2,"E; D","Estimated value; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.4,"E; D","Estimated value; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",49.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",54.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",53.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",48.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",48.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",49.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",54.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",57.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",63.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",70.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",58.8,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",61.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",48.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",49,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",47.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",50,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",51,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",53.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",50.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",50.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",49.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",52.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",57.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",52,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",31.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",28.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",29.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",36.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",38,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",41.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",52.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",57.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",56.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",53.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",55.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",30.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",33.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",38.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",38.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",47.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",58.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",52.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",47.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",47.5,"B; D","Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",44.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",42.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",42.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",93.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",87.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",79.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",74.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",82.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",81.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",99.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",105.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",113.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",119,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",120.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",115.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",133.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",18.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",17,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",19.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",21,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",24,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",30.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",16.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",16.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",13.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",13.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",15.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",51.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",60.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",63.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",59,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",58.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",60.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",65,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",64.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",69.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",79.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",84,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",93.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",18.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.2,"B; D","Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",23.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",27.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",29.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",31.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",19,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",19.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",53.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",52.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",54.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",54.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",97.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",103.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",83.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",70.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",69.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",64.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",65.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",71.4,"E","Estimated value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",16.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",19.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",18.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",18.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",18,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",16.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",15.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",12.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",9.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",11.8,"B; D","Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",12.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",61.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",67.5,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",63.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",63.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",64.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",66.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",69.2,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",68.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",68.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",70.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",65.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",24.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",24.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",20.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",20.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",20.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",19.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",21.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",30,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",34.2,"D; P","Difference in methodology; Provisional value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",8.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",18.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",18.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",20.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",20.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",19.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",18.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",19.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",17.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",16.8,"E","Estimated value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",24.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",25.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",27.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",29.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",28.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",6.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",7.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",8.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",15.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",15.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",16.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",16.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",18.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",21.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",14.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",12.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",28.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",31.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",33.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",33,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",38.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",43,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",45.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",43.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",41.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",32.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",59.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",60.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",27.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",24.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",19,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",22,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",19.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",20.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",22.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",21.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",17.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",20.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",39.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",42.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",44.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",42.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",46.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",50.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",42,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",40,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",40.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",42.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",10.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",9.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",8.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",8.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",9.8,"B; D","Break; Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",9.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",10,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",10,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",63.2,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",64.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",61,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",60.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",63,"P","Provisional value"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",31.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",30.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",30.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",28.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",35.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",45.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",44.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",36.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",50.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",42.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",36.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",36.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",39.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",38.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",40.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",42.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",42.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",43.7,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",55.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",54.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",55.2,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",55.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",55.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",49.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",56.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",38.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",27.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",24.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",24.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",24,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",25.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",27.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",29.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",34.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",35.9,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",38.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",40.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",46.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",51.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",57.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",58.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",9.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",29.6,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",21.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",27.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",39,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",34.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",47.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",46.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",53.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",36.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",45.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",29.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",35.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",34.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",40.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",45,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",63.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",62.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",65.9,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",68,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",63.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",104.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",79.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",14.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",15.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",17.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",16.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",24.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",23.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",25,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",24,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",19.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",22.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",5.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",5.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",5.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",9.6,"B; D","Break; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",9.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",10.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",11.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",10.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",10.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",10.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",8.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",8.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",10.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",10.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",9.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",10.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",8.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",8.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",8.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",6.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",6.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",26.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",24.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",24.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",23.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",23.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",22.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",21.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",21.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",22.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",20,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",20.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",24.5,"E","Estimated value"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",16.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",15.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",15.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",15.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",15.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",15.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",14.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",12.2,"E; D","Estimated value; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",9.8,"E; D","Estimated value; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",9.4,"E; D","Estimated value; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",10.1,"E; D","Estimated value; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",18.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",18.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",18.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",18.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",16.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",15.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",15.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",16.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",18.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",18.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",15.1,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",15.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",13.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",11.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",11.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",10.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",11.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",11.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",12.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",13.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",12.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",12.2,"B; D","Break; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",11.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",9.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",45.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",43,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",38.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",32.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",35.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",34.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",36.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",36.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",37.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",38.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",36.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",38.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",37.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",11.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",11.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",10.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",10.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",10.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",10.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",9.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",9.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",9.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",8.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",6.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",6.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",7.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",22.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",22.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",23.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",23.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",22,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",22.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",22.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",22.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",23.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",21.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",19.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",12.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",11.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",14.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",12.8,"B; D","Break; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",12.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",12.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",11.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",10.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",9.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",8.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",9.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",21.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",21.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",20.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",20.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",21,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",21.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",17.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",17.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",20.3,"E","Estimated value"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",36.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",36.4,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",32.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",30.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",30.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",28.7,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",28.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",29.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",29.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",24.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",14.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",12.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",12,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",11.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.5,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",9.2,"D; P","Difference in methodology; Provisional value"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",9.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",9.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",8.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",2.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",2.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",2.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",2.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",10.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",10,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",10.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",9.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",8.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",8.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",8.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",8.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",7.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",8.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",15.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",13.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",11.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",11.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",10.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",11,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",10.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",10.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",10.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",10.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",7.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",10.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",19.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",20.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",23.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",24.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",15.5,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",11.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",13.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",7.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",7.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",8.1,"B; D","Break; Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",8.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",16.2,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",16.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",15.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",15.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",17.2,"P","Provisional value"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",11.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",11.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",10.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",8.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",7.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",28.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",18.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",16.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",14.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",13.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",14.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",14.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",13,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",12.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",11,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",10.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",6.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",11.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",11.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",11.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",11.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",10.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",10.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",11.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",11.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",11.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",10.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",10.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",9.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",9.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",9.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",9.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",9.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",8.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",9.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",9.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",8.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",8.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",9.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",9.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",8.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",11.3,"B; D","Break; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",11.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",11.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",13.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",14.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",15.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",15.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",15.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",15.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",14.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",14.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",15.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",15.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",15.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",16.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",16,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",17.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",28.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",28.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",29.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",27.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",25.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",29.2,"E","Estimated value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",22.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",23,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",22.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",20.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",20.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",21,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",21.9,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",22.9,"E; D","Estimated value; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",22.7,"E; D","Estimated value; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",25,"E; D","Estimated value; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",24.1,"E; D","Estimated value; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",28.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",28.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",29.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",29.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",30.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",29.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",31.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",33,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",39.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",40.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",16.5,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",17.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",14.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",15.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",12.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",13.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",12.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",13.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",14.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",15.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",16.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",18.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",17.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",15.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",18.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",18.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",19.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",20,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",19.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",20.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",20.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",21.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",22.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",21.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",21.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",17.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",20.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",20.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",21.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",21.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",22.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",22,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",22.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",22.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",21.2,"B; D","Break; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",21.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",20.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",23.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",39.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",34.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",32.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",31.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",31.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",28.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",34,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",34.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",39.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",39.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",40.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",42.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",41.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",17.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",17.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",15.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",15.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",13.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",13.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",13.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",13.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",13.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",13.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",12.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",11.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",11.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",28.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",17.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",21.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",15.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",13.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",14.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",14.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",15.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",22,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",22.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",22.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",19.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",17.9,"B; D","Break; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",17.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",17.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",17.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",17.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",17.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",17.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",18,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",18.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",14.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",13.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",12.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",11.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",10.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",11,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",11.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",13,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",13.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",13.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",13.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",15.9,"E","Estimated value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",29.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",32.4,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",29.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",29.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",30.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",31.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",30.7,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",31.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",34.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",37,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",39.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",41.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",22,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",21.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",21.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",23.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",23.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",25,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",23.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",22.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",21.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",17.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",18.6,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",18.7,"D; P","Difference in methodology; Provisional value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",6.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",4.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",4.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",3.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",3.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",3.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",2.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",2.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",1.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",2.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",1.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",1.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",1.7,"E","Estimated value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",11.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",10.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",9.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",9.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",8.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",3.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",3.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",3.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",3.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",3.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",2.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",13.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",14,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",14.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",15.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",15.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",16.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",17.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",19.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",22.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",22.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",21.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",26,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",24.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",38.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",34.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",32.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",30.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",28.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",27.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",28.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",27.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",27.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",28.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",26.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",27.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",31,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",23.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",23.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",22,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",24.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",26.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",25.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",28.1,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",28.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",29.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",34.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",33.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",37,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",25,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",22.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",19.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",17.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",16.5,"B; D","Break; Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",14.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",15.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",15.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.3,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",17.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",18.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",21.6,"P","Provisional value"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",14.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",14.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",14.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",15.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",15.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",15.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",17.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",17.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",19.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",20.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",21.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",21.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",30.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",31.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",32.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",33.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",36.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",38.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",41.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",42.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",41.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",43.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",41.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",43.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",44.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",16.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",13.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",11.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",11.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",11.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",11.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",13.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",14.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",14.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",15.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",13.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",14.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",8,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",8.4,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",8.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",9.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",10.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",10.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",11.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",11.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",10.2,"B","Break"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",14.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",14.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",16.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",17.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",16.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",15.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",16.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",12.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",13,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",17.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",14.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",15.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",16.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",17.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",19.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",20.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",22.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",23.6,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",23.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",24.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",25.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",26.2,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",26.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",32.8,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",16.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",15.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",14.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.3,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",12.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",12.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",13.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",13.9,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.4,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",16.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",16.7,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",25.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",3.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",2.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",2.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",3.8,"B; D","Break; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",3.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",3.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",3.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",2.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",2.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",2.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",2.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",2.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",6.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",6.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",6.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",6.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",6.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",6.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",5.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",5.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",5.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",5.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",5.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",12.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",12.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",12.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",12.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",12.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",12.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",12.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",11.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",11,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",11.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",9.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",9.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",11.4,"E","Estimated value"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",10.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",10.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",10.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",7.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",7.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",7.4,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",7.8,"E; D","Estimated value; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",6.2,"E; D","Estimated value; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",7.1,"E; D","Estimated value; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",6.3,"E; D","Estimated value; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",12.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",12.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",13.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",13.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",13.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",13.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",13.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",14,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",14.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",15.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",6.6,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",6.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",10.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",11,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",11.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",10.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",10.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",10.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",10.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",10.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",9.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",9.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",9.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",9.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",8.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",8.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",9.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",9.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",10,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",9.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",9.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",8.7,"B; D","Break; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",8.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",8.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",12.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",9.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",9.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",9.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",9.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",10.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",10.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",10.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",10.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",9.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",9.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",10,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",5.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",4.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",21.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",11.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",11,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",14.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",9.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",9.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",9.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",8.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",8.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",9.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",9.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",8.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",7.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",7.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",5.7,"B; D","Break; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",5.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",5.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",3.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",3.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",3.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",5.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",5.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",5.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",5.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",4.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",4.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",4.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",3.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",3.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",3.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",3.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",4.3,"E","Estimated value"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",14.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",14.9,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",13.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",13.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",13.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",14.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",13.6,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",13.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",15.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",15.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",16.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",16.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",12.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",12.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",13.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",13.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",13.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",12,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",11.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",8.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",8.1,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.4,"D; P","Difference in methodology; Provisional value"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",5.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",1.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",1.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",1.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",1.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",1.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",9.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",9.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",9.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",10.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",9.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",10,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",10.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",10.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",10.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",10.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",10.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",11.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",10.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",19.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",17.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",16.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",16.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",16.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",16.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",15.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",15.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",16,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",14.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",13.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",16.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",10.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",9.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",11,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",11.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",10.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",12.5,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",10.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",12.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",12.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",12.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",11.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",11.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",10.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",10.6,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",10,"B; D","Break; Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",8.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",8.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",7.6,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",7.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",7.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",7.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",9.1,"P","Provisional value"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",8.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",8.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",8.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",8.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",9.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",8.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",7.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",7.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",5.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",5.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",4.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",4.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",5.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",7.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",6.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",7.9,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",8.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",8.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",8.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",9.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",7.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",5.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",8.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",11.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",11.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",13.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",13.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",13.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",13.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",14.7,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",7.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",6.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",6.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",6.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",7.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",7.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",7.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",6.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",7.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",6.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",6.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",7.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",51.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",53,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",50.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",59.7,"B; D","Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",56.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",54.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",54.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",52.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",53,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",51.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",53.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",55.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",66.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",70.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",71,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",70.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",70,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",67.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",65.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",64.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",64.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",65.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",68.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",74.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",111.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",114.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",110.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",108.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",106.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",104.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",102.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",102.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",98.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",100.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",102.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",103.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",120.5,"E","Estimated value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",120.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",121.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",122.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",122,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",128.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",128.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",124,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",119.6,"E; D","Estimated value; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",128.5,"E; D","Estimated value; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",137.9,"E; D","Estimated value; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",145,"E; D","Estimated value; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",69.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",70.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",72.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",71.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",71.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",70.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",72.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",78.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",81.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",83.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",64.3,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",67.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",110.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",110.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",96.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",89.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",88.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",86.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",85.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",83.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",85.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",88.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",91.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",89.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",71.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",73.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",71.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",69.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",67.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",64.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",63.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",62.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",62.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",66.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",70.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",86.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",71.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",86.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",89.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",85.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",86.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",91.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",85,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",84.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",81.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",83.5,"B; D","Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",87,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",89.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",93.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",130,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",115.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",104.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",102.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",99.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",85.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",107.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",104.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",110.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",117.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",114,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",116.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",98.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",49.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",52,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",47,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",47.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",46.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",46.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",46.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",44.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",44.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",44.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",42.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",39.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",34.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",160.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",132.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",129,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",144.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",117.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",113.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",118.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",110.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",107.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",117.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",130.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",142.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",89.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",94.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",102.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",95.4,"B; D","Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",92.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",91.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",89.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",81.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",74.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",70.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",70,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",70,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",44.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",43.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",42.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",41.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",42.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",42.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",42.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",43.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",47.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",49,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",50.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",54.6,"E","Estimated value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",56.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",64.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",66.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",64.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",62.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",61.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",62,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",58.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",61.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",87.6,"B; D","Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",84.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",75.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",37.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",42.6,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",41.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",43.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",45.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",48.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",47.5,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",50.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",55.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",61.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",69.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",74.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",74.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",76.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",73.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",70.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",70.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",72.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",70.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",69.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",68.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",70.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",69.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",72.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",74.1,"D; P","Difference in methodology; Provisional value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",16.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",14.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",13.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",14.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",14.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",14.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",15.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",15,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",13.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",14.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",14.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",14.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",14.9,"E","Estimated value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",42.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",45.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",42.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",42.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",41.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",25.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",28,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",23.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",22.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",20.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",24.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",25.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",24.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",24.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",24.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",23.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",25.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",26.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",77.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",76.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",79.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",77.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",78.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",76.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",78.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",83.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",84.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",87.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",97.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",107.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",100.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",106.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",98.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",89.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",83.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",84.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",84,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",85.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",87.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",89.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",96.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",98.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",97.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",105.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",49.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",49.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",45.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",51.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",53,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",52.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",57.3,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",52.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",50.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",52.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",52.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",54.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",92.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",92.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",87.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",91,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",98.9,"B; D","Break; Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",95.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",101.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",104.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",115.4,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",117.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",121,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",123.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",131.3,"P","Provisional value"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",85.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",90.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",87.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",88.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",86.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",86.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",84.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",85.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",86.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",93.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",98.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",93.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",101.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",90.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",96.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",97.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",98.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",97.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",101.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",120.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",121.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",119,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",121.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",126.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",134.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",26.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",23.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",19.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",19.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",19.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",21.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",25.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",27,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",27.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",30.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",30.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",29.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",57.8,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",61.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",65.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",71.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",72,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",70.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",69.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",25.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",31.2,"B","Break"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",34,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",34.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",38.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",40.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",42,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",42.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",43.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",43.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",46.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",52.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",49,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",31.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",32.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",33.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",33.6,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",34.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",35.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",36.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",37.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",39.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",42.5,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",46.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",47.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",51.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",61.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",62.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",59.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",59.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",57.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",53.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",54.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",53.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",55,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",56.8,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",58.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",59.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",64.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",11.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",12.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15,"B; D","Break; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",15.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",15.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",14.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",14.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",14.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",13.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",8.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",8.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",8.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",8.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",9.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",9.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",9.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",9.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",10.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",12.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",26.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",27.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",26.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",26.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",27.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",27.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",28.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",29.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",34.5,"E","Estimated value"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",25.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",25.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",25.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",25.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",25.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",24.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",22.3,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",20.2,"E; D","Estimated value; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",21.7,"E; D","Estimated value; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",22.1,"E; D","Estimated value; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",21.9,"E; D","Estimated value; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",16.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",19.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",20.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",21.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",22.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",22.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",23.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",26.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",26.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",25.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",17.5,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",18.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",13.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",14,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",14.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",14.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",14.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",14.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",14.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",14,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",13.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",16.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",18.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",17.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",23.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",24.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",26.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",26.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",29.8,"B; D","Break; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",31.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",31.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",36.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",9.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",10.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",11.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",12,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",13.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",12.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",22.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",22.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",24.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",28.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",21.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",20,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",20.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",4.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",4.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",4.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",4.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",4.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",3.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",3.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",3.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",3.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",23.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",18.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",17.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",22.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",18.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",17.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",18.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",19,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",18.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",19.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",14.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",15,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",15.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",14.6,"B; D","Break; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",14.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",15.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",15.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",14.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",14,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",13.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",13.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",14.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",6.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",6.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",7.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",7.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",7.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",9.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",9.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",10.1,"E","Estimated value"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",7.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.6,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",7.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",7.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",8.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",8.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",8.7,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",8.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",9.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",10.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",11.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",12.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",15.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",16.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",16.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",17,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",16.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",16.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",17.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",17,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",17.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",18.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",19.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",21.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",21.9,"D; P","Difference in methodology; Provisional value"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",10.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",11.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",11.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",11.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",10.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",4.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",3.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",3.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",2.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",2.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",2.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",3.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",3.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",26.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",27.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",27.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",27.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",27.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",27,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",27.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",28.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",28.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",29.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",34.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",39,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",38,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",16.7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",16.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",17.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",17.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",20.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",20.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",21.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",21.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",24.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",28.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",10.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",11.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",11.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",12.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",12.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",12.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",14.9,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",14.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",14.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",14.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",14.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",15.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",14.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",14.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",14.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",18.5,"B; D","Break; Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",20.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",23,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",24.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",25.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",26.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",27.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",28,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",30.3,"P","Provisional value"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",23.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",24.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",23.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",23.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",23.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",23.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",22.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",25.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",27.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",28.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",27.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",30.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",4.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",4.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",5.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",5.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",6.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",5.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",8.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",9.8,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",10.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",10.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",10.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",10.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",11.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",10.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",11.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",9.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",9.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",7.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",7.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",8.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",9.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",9.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",10.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",11.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",12.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",13.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",14.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",17.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",13.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",13,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",12.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",14.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",14.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",15,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",15.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",15.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",15.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",16.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",17.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",18.6,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",21.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",1,"B; D","Break; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",1.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",1.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",1.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",7.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",7.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",7.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",7.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",7.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",7.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",7.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",7.6,"E","Estimated value"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",3.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",3.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",3.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",3.7,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",3.7,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",3.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",3.5,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.3,"E; D","Estimated value; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.3,"E; D","Estimated value; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",3.1,"E; D","Estimated value; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",2.9,"E; D","Estimated value; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",2.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",2.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",3.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",3.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",2.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",2.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",1.9,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",1.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",1.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",1.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",1.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",1.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.1,"B; D","Break; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",2.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",2.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",2.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",3.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",3.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",3.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",3.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",3.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",3.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",4.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",4.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",2.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",2.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",1.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",1.7,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",1.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",6.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",5.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",6.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",5.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",5.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",5.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",5.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",5.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",5.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",5.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",6.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",2.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",2.5,"B; D","Break; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",2.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",2.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.1,"E","Estimated value"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",1.6,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.3,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",5.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",5.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",5.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",5.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",5.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",5.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",5.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",5.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",5.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",5.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",5.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",5,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",4.7,"D; P","Difference in methodology; Provisional value"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",1.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",1.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",1.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",1.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",2.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",2.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",2.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",2.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",2.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",2.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",2.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",2.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",2.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",2.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",2.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",9.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",8.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",8.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",8.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",9.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",8.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",8.7,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",8.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",8.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",8.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",8.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",8.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",2.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.7,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",2.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",3.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",3.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",3.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",3.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",3.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",3.4,"B; D","Break; Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",3.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",3.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",3.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",3.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",3.5,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",3.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",3.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",3.8,"P","Provisional value"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",2.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",2.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",2.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",2.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",2.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",1.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",1.6,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",2.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",1.7,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",1.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",1.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",2.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.5,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",0.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",0.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",0.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",0.6,"B; D","Break; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",0.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",0.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",0.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",0.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",0.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",0.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",0.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",0.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",7.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",7.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",7.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",8.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",8.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",8.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",8.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",8.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",8.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",7.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",8.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",8.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",8.9,"E","Estimated value"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",4.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",4.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",4.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",4.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",4.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",4.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",4,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",3.7,"E; D","Estimated value; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",3.8,"E; D","Estimated value; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",4,"E; D","Estimated value; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",4.2,"E; D","Estimated value; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",3.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",3.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",3.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",3.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",3.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",3.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",3.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",0.3,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",0.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",2.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",2.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",2.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",2.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",2.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",2.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",2.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",2.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",3.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",1.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",1.3,"B; D","Break; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",1.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",1.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",1.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",1.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",1.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",1.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",1.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",1.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",2.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",1.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",0,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",10.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",10.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",10.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",10.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",10,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",9.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",10,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",10.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",11.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",12.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",13.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",15,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",4.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",4.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",4.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",4.9,"B; D","Break; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",4.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",4.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",4.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",4.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",4.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",4.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",4.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",0.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",0.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",0.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",0.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",0.2,"E","Estimated value"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",0.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",0.9,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",0.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",0.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",1.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",1.1,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",1.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",1.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",1.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",1.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",1.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",6.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",6.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",6.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",6.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",7.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",7.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",7.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",6.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",6.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",6.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",6.7,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",6,"D; P","Difference in methodology; Provisional value"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",0.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",0.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",0.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",0.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",0.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",0.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",0.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",0.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",0.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",0.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",0.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",0.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",3.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",3.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",4.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",4.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",4.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",4.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",4.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",6.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",7.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",6.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",2.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",2.7,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",2.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",3.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",3.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",3.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",3.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",3.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",3.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",3.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",3.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",3.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",3.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",1.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",1.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",1.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",1.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",1.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",2.3,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",1.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",2.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",2.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",2.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",2.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",1.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",1.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",1.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",1.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",1.5,"B; D","Break; Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",1.5,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",1.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",1.9,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",2.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",2.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",2.1,"P","Provisional value"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",3.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",3.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",3.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",4.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",5.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",6.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",7.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",6.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",7.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",0.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",0.9,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",1.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",1.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",1.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",1.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",1.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",2.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",4.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",4.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",3.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",2.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",2.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",2.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",2.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",2.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",2.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",2.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",3.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",3.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",3.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",3.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",3.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",2.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",2.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",2.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",2.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",2.1,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",2.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",2.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",14.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",14.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",12.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",15.7,"B; D","Break; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",13.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",12.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",12.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",11.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",12.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",12.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",13.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",14.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",13.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",14.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",15,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",15.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",16,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",13.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",12.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",11.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",11.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",11.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",11.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",11,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",20.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",20.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",20.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",20.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",20,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",17.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",14.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",14.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",13.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",14.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",13.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",13.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",14.7,"E","Estimated value"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",33.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",33.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",34.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",32.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",32.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",31.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",28.7,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",28.4,"E; D","Estimated value; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",29.6,"E; D","Estimated value; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",31.4,"E; D","Estimated value; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",33,"E; D","Estimated value; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",12.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",11.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",12.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",11.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",10.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",9.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",8.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",9.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",11,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",11.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",11.5,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",12.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",6.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",6.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",6.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",6.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",6.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",6.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",6.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",6.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",7.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",7.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",8.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",12.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",12.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",11.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",12.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",13.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",12.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",12.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",11.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",11.8,"B; D","Break; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",12.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",11.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",11.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",23.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",19.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",18.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",19.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",17.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",16,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",17,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",16.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",17.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",18.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",19.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",19.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",17,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",9.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",10.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",8.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",8.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",8.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",7.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",6.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",5.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",5.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",5.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",5.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",20.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",19.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",17.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",16.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",16.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",15.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",16.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",17.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",18.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",20.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",21.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",17.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",17.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",19.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",19.4,"B; D","Break; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",18.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",14.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",13.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",11.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",11.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",11.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",11.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",12.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",11,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",11.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",11.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",10.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",9.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",8.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",8.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",9.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",10,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",10.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",10.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",11.3,"E","Estimated value"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",3.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",4.1,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",3.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",4.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",4.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",4,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",4.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",4.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",5.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",6.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",16.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",15.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",15.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",14.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",13.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",12.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",11.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",11.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",10.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",10.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",10.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",9.6,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",8.9,"D; P","Difference in methodology; Provisional value"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",6.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",6.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",6.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",7.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",7.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",4.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",4.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",4.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",2.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",2.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",1.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",1.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",1.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",1.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",1.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",7.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",5.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",5.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",5.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",5.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",5.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",5.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",5.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",5.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",24,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",21.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",18.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",16,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",15.8,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",15.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",15.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",16.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",17,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",18.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",19.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",20.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",22.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",5.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",4.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",4.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",5.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",5.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",6.1,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",5.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",5.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",5.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",20.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",17.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",15,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",15.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",17.4,"B; D","Break; Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",15.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",16.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",17,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",17.8,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",18.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",19.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",20.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",23.2,"P","Provisional value"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",7.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",7.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",8.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",8.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",7.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",6.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",8.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",9.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",8.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",8.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",5.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",4.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",3.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",3.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",3.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",3.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",3.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",4.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",5.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",4.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",5.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.3,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",4.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",7.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",8.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",8.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",8.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",9.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",10.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",12,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",4.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",4.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",4.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",4.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",4.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",4.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",4.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",4.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",5.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",5.5,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",6.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",6.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",11.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",12.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",11.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",11.9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",11.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",9.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",9.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",9,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",9.4,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",10.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",10.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",10,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",10.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",17.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",19.1,"B; D","Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",19.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",19.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",20.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",20.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",19.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",24.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",28.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",29.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",22,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",22.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",23.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",24.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",24,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",24.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",25.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",26,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",27.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",30.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",33,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",37.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",56.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",56.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",56.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",59,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",56.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",58.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",57.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",57.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",59.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",62.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",59,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",59.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",86.4,"E","Estimated value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",38.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",40.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",41.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",42.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",44.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",44.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",47.6,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",48.4,"E; D","Estimated value; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",51.8,"E; D","Estimated value; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",50.3,"E; D","Estimated value; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",53.8,"E; D","Estimated value; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",45.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",47.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",48.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",50.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",51.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",52.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",52.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",56.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",58,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",60,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",38.6,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",39.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",45.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",46,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",46.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",46.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",47,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",47.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",48.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",48.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",50.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",53.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",55.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",56.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",30.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",30.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",31.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",29.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",30,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",29,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",31,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",31.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",32.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",33,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",32.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",33,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","FRA","France","2011","2011",36.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",31.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",31.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",30.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",32.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",32.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",32.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",34.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",34.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",37.9,"B; D","Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",41.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",43.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",47.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",57.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",57,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",52.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",51.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",54.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",50.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",63.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",66.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",69.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",73.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",71.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",70.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",85.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",26.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",28.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",27.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",27.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",26.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",25.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",26.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",25.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",25.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",26.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",26.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",23.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",23.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",41.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",36.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",36,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",41.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",33.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",30.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",32.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",32.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",34.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",37.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",40.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",41.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",40.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",39.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",41.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",43.6,"B; D","Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",43.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",44.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",44.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",47.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",58.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",61.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",54.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",53.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",25.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",24.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",24.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",24.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",25.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",26.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",26.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",28.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",31.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",34,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",33.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",39.1,"E","Estimated value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",8.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",9.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",9.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",7.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",9.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",8.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",10.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",8.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",10.5,"B; D","Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",9.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",7.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",24.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",23.2,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",22.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",21.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",23.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",24,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",24.9,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",25.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",27.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",28.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",25.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",23.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",34.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",34.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",33.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",34.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",32.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",31.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",31.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",28.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",29.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",29.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",28.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",35.6,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",39.5,"D; P","Difference in methodology; Provisional value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",10.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",8.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",8.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",7.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",7.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",5.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",5.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",4.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",4.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",3.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",4.3,"E","Estimated value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",39.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",42,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",40.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",40.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",37.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",11.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",12.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",13.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",14,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",14.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",14.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",15.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",14.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",15.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",17,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",17.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",21.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",42.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",42.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",42.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",40.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",42,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",40.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",43.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",47.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",48.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",51.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",51.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",56.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",57.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",32.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",32.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",33.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",33.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",31.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",35.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",37.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",37.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",39.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",42.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",40.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",38,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",47.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",30.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",31.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",27.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",32.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",34.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",36.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",43.6,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",42.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",41.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",43.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",39.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",46.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",38.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",39.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",37,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",34.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",37.4,"B; D","Break; Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",38.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",38.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",38.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",45.3,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",47.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",49.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",49.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",58.5,"P","Provisional value"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",39.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",41.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",43.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",43,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",41.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",38.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",39.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",39.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",42.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",47.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",48,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",46.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",53.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",42.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",44,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",45.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",48.3,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",45.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",49.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",49.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",50.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",51.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",53.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",49.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",47.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",63.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",25.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",22.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",18,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",17.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",18.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",18.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",20.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",21.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",22.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",25.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",23.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",22.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2012","2012",32.2,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2013","2013",34.3,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2014","2014",35,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2015","2015",35.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2016","2016",36.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2017","2017",36.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","GBR","United Kingdom","2018","2018",35.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",17.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",20.8,"B","Break"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",22.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",22.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",23.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",25,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",26.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",27.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",27.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",26.9,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",20.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",21.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",27.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",21.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",22.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",24.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",27.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",28.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",28.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",30.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",31.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",33.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",34.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",34.7,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",36.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",42.8,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",22.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",22.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",22.6,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",22.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",21.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",21.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",22.8,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",21.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",20.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",22.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",24.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",30.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",34.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",16.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",16.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",16.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",18.4,"B; D","Break; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",18.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",17.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",17.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",17.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",17.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",17.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",19.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",20.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",18.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",19.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",20.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",21.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",20.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",21.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",21.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",21.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",22.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",24.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",26,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",26.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",27.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",27.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",27.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",28.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",28,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",27.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",27.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",28.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",29.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",32.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",32.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",33.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",37.3,"E","Estimated value"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",31.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",32.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",33.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",33.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",35.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",36,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",37.9,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",38.4,"E; D","Estimated value; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",41.1,"E; D","Estimated value; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",39.4,"E; D","Estimated value; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",42.3,"E; D","Estimated value; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",22.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",22.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",23.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",22.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",24.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",25.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",26.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",28.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",28.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",29.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",29.1,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",29.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2010","2010",19.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2011","2011",19.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2012","2012",19.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2013","2013",18.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2014","2014",18.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2015","2015",17.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2016","2016",18.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2017","2017",19.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2018","2018",19.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2019","2019",19.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2020","2020",20.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","FIN","Finland","2021","2021",19.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",26.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",26.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",25.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",27,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",27.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",26.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",28.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",28.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",31.2,"B; D","Break; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",33.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",34.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",35.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2010","2010",40.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2011","2011",39.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2012","2012",36.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2013","2013",35.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2014","2014",37.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2015","2015",32.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2016","2016",41,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2017","2017",43.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2018","2018",46.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2019","2019",48.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2020","2020",50.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2021","2021",51.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","GRC","Greece","2022","2022",51.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2010","2010",21.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2011","2011",23.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2012","2012",22.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2013","2013",23.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2014","2014",23.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2015","2015",22.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2016","2016",22.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2017","2017",22.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2018","2018",22.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2019","2019",22.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2020","2020",23.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2021","2021",21,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HUN","Hungary","2022","2022",20.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",26.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",27.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",27.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",27.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",25.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",23.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",24.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",23.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",25.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",28.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",31.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",32.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",34.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",33.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",35,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",31.7,"B; D","Break; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",29.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",30.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",29.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",26.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",26.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",25.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",27.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",26.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2011","2011",22.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2012","2012",22.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2013","2013",22.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2014","2014",22.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2015","2015",22.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2016","2016",23.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2017","2017",23.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2018","2018",24.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2019","2019",26.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2020","2020",28.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2021","2021",26.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ITA","Italy","2022","2022",28,"E","Estimated value"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",6.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",7.2,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",6.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",6.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",6.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",7.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",7.1,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",7.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",8.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",7.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2010","2010",24.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2011","2011",25.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2012","2012",25,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2013","2013",25.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2014","2014",23.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2015","2015",22.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2016","2016",22.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2017","2017",20.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2018","2018",20.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",20.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",20.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",22.5,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",23.3,"D; P","Difference in methodology; Provisional value"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2010","2010",30.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2011","2011",32.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2012","2012",32.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2013","2013",32.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NLD","Netherlands","2014","2014",30.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",10.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",11.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",11.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",12.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",13,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",13.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",13.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",12.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",14,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",14.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",15.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",15.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",18.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",25.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",25.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",24.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",22.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",23,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",21.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",22.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",23.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",23.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",24.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",25.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",27.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",25.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",20,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",20.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",20.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",20.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",19.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",20.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",22.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",22.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",23,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",24.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",25.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",24.1,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",26.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",12.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",13.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",12.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",14.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",15.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",16.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",18.2,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",17.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",15.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",15.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",15,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",14.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2010","2010",30.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2011","2011",31.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2012","2012",31,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2013","2013",30,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2014","2014",32,"B; D","Break; Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2015","2015",32.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2016","2016",32.9,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2017","2017",32.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2018","2018",38.7,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2019","2019",40.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2020","2020",40.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2021","2021",40.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ESP","Spain","2022","2022",44,"P","Provisional value"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2010","2010",22.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2011","2011",23.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2012","2012",25,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2013","2013",24.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2014","2014",23.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2015","2015",19.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2016","2016",19.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2017","2017",19.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2018","2018",20,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2019","2019",21.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2020","2020",23.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2021","2021",22.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SWE","Sweden","2022","2022",23.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",13.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",12,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",9.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",8.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",9.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",9.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",9.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",10.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",10.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",12,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",12.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",11.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",2.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",4.4,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",4.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",5.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",6.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",7.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",7.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",7.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",7.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",9.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",10.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2010","2010",9.4,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2011","2011",9.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2012","2012",10.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2013","2013",12.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2014","2014",12.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2015","2015",12.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2016","2016",12.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2017","2017",13.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2018","2018",14.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2019","2019",14.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2020","2020",15.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2021","2021",15.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","EST","Estonia","2022","2022",15.3,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2010","2010",17.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2011","2011",18,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2012","2012",18.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2013","2013",18.2,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2014","2014",17.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2015","2015",17.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2016","2016",18.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2017","2017",17.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2018","2018",16,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2019","2019",17.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2020","2020",18.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2021","2021",19.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","SVN","Slovenia","2022","2022",20.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2010","2010",68.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2011","2011",74.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2012","2012",80.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2013","2013",96.8,"B; D","Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2014","2014",106,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2015","2015",113.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2016","2016",124.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2017","2017",126.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2018","2018",143.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2019","2019",160,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2020","2020",181.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUS","Australia","2021","2021",197.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2010","2010",82.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2011","2011",88.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2012","2012",96.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2013","2013",105.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2014","2014",112.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2015","2015",120.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2016","2016",135.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2017","2017",144.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2018","2018",157.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2019","2019",173.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2020","2020",189.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","AUT","Austria","2021","2021",203.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2010","2010",131.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2011","2011",134.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2012","2012",140.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2013","2013",147.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2014","2014",160.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2015","2015",173,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2016","2016",187.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2017","2017",216.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2018","2018",249.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2019","2019",303.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2020","2020",354.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2021","2021",382.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","BEL","Belgium","2022","2022",440.1,"E","Estimated value"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2012","2012",106.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2013","2013",119.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2014","2014",127.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2015","2015",137.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2016","2016",155.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2017","2017",171,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2018","2018",189.4,"E; B; D","Estimated value; Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2019","2019",202.3,"E; D","Estimated value; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2020","2020",224.9,"E; D","Estimated value; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2021","2021",246.1,"E; D","Estimated value; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CAN","Canada","2022","2022",259.6,"E; D","Estimated value; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2010","2010",139.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2011","2011",136.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2012","2012",143.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2013","2013",144.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2014","2014",152.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2015","2015",167.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2016","2016",180.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2017","2017",194,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2018","2018",210.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2019","2019",230.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2020","2020",221.1,"B","Break"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CZE","Czechia","2021","2021",237.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2010","2010",135,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2011","2011",134.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2012","2012",141.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2013","2013",158.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2014","2014",173.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2015","2015",175.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2016","2016",186.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2017","2017",212.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2018","2018",229.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2019","2019",229.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2020","2020",239.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DNK","Denmark","2021","2021",240.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2010","2010",100,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2011","2011",107.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2012","2012",116,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2013","2013",128.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2014","2014",140.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2015","2015",152.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2016","2016",170.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2017","2017",191,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2018","2018",289.9,"B; D","Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2019","2019",317.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2020","2020",343.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","DEU","Germany","2021","2021",371.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2010","2010",134.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2011","2011",191.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2012","2012",159,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2013","2013",147.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2014","2014",138.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2015","2015",146.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2016","2016",156.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2017","2017",169.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2018","2018",205.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2019","2019",213.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2020","2020",249,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ISL","Iceland","2021","2021",273.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2010","2010",131.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2011","2011",135.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2012","2012",143.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2013","2013",150.8,"B; D","Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2014","2014",158.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2015","2015",174.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2016","2016",194.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2017","2017",205.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2018","2018",225.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2019","2019",261.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2020","2020",269,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","IRL","Ireland","2021","2021",294.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2010","2010",202.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2011","2011",220.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2012","2012",225.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2013","2013",239.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2014","2014",231.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2015","2015",247.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2016","2016",249.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2017","2017",265.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2018","2018",296.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2019","2019",408.7,"B; D","Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2020","2020",411.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","JPN","Japan","2021","2021",429.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2010","2010",134.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2011","2011",140.4,"B","Break"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2012","2012",146.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2013","2013",150.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2014","2014",159.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2015","2015",167.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2016","2016",177.7,"B","Break"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2017","2017",186.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2018","2018",206.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2019","2019",224.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2020","2020",236.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","KOR","Korea","2021","2021",251.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2019","2019",85.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2020","2020",88.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2021","2021",111.3,"B; D; P","Break; Difference in methodology; Provisional value"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","LUX","Luxembourg","2022","2022",140.6,"D; P","Difference in methodology; Provisional value"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2010","2010",19.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2011","2011",19.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2012","2012",17.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2013","2013",19.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2014","2014",17.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2015","2015",17.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2016","2016",18.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2017","2017",17.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2018","2018",17.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2019","2019",17,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2020","2020",15.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2021","2021",15.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","MEX","Mexico","2022","2022",17.8,"E","Estimated value"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2010","2010",28.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2011","2011",31.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2012","2012",44,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2013","2013",48.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2014","2014",49.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2015","2015",50.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2016","2016",56.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2017","2017",94.8,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2018","2018",85.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2019","2019",107.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2020","2020",125.7,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2021","2021",129.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NZL","New Zealand","2022","2022",137,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2010","2010",98.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2011","2011",100,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2012","2012",106.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2013","2013",114.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2014","2014",126.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2015","2015",126,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2016","2016",135.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2017","2017",155.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2018","2018",165.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2019","2019",165,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2020","2020",169.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2021","2021",190.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","NOR","Norway","2022","2022",168.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2010","2010",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2011","2011",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2012","2012",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2013","2013",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2014","2014",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2015","2015",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2016","2016",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2017","2017",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2018","2018",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2019","2019",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2020","2020",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2021","2021",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","PRT","Portugal","2022","2022",0,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2010","2010",97,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2011","2011",94.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2012","2012",100.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2013","2013",132.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2014","2014",148.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2015","2015",156,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2016","2016",170.7,"B","Break"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2017","2017",164,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2018","2018",170.9,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2019","2019",194.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2020","2020",178,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","SVK","Slovak Republic","2021","2021",191.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2010","2010",85.5,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2011","2011",93.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2012","2012",109,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2013","2013",116.6,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2014","2014",119.9,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2015","2015",126.1,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2016","2016",121,"B; D","Break; Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2017","2017",129.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2018","2018",137.2,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2019","2019",147.4,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2020","2020",166.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2021","2021",184,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHE","Switzerland","2022","2022",207.3,"D","Difference in methodology"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2010","2010",41,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2011","2011",38.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2012","2012",37.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2013","2013",38.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2014","2014",43.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2015","2015",49.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2016","2016",55.7,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2017","2017",51.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2018","2018",55.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2019","2019",63.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2020","2020",66,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","TUR","Türkiye","2021","2021",66.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2010","2010",15.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2011","2011",27.8,"B","Break"
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2012","2012",28.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2013","2013",38.2,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2014","2014",33.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2015","2015",34.3,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2016","2016",37.8,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2017","2017",44.5,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2018","2018",50.4,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2019","2019",63.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2020","2020",61.1,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2021","2021",56.6,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","CHL","Chile","2022","2022",51.2,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",270.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",282.3,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",286.8,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",306.1,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",318.5,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",337,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",388.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",417.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",435.6,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",457.9,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",487.7,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",478.4,"D","Difference in methodology"
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",546.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",35,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",37.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",37.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",40.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",43,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",46.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",51.7,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",53.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",55,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",60.1,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",65.6,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",68.3,"D","Difference in methodology"
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",78.8,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.4,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.5,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.5,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.6,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.7,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.7,"D","Difference in methodology"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.7,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.3,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",4.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",4.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",4.9,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.4,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",5.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",5.6,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.5,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",7.6,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",14.9,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",16.4,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",16.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",17.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",18.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",20.1,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",22.2,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",23.8,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",24,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",26,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",30.5,"D","Difference in methodology"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",35.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",18.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",19,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",22.3,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",23.5,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",26,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",30.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",33.4,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",41.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",43.6,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",45.1,"D","Difference in methodology"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",48,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",51.2,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",52.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",53.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",55,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",54.6,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",54.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",57.9,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",60.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",60.3,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",63.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",62.8,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",60.5,"D","Difference in methodology"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",63,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",0.1,"D","Difference in methodology"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",0.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",0.4,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",0.4,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",0.5,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",0.6,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",0.7,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",0.8,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",0.9,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",1.1,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.2,"D","Difference in methodology"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.5,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.8,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.9,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",3.3,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.7,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",4.1,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.4,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.6,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.7,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.1,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.3,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.2,"D","Difference in methodology"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",3.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",6.4,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",6.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",6.8,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.2,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.3,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7.7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.5,"D","Difference in methodology"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",3.8,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",3.6,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",3.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",3.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",2.5,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",2.4,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",2.2,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",2.1,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",1.7,"D","Difference in methodology"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",1.7,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",17.9,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.5,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",19.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",19.3,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",19,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",19.8,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",21.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",21.2,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",22.1,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",21.4,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",19.6,"D","Difference in methodology"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",19.2,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7.1,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",5.4,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",5.9,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.6,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",8.5,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",9.3,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",9.8,"D","Difference in methodology"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",12.2,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",12.7,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",12.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",13.8,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",14.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.4,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",14.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",15.9,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",15.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",16.3,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",15.6,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",15.1,"D","Difference in methodology"
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",5.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",5.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6.3,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.9,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",7,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",7.6,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7.2,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",7.1,"D","Difference in methodology"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",8.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",4.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",4.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",5.3,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",6.1,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",5.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",6,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",6.4,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",6.5,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",6.7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",6.9,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",7,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",6.8,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",6.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",25,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",26.1,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",28.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",31.8,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",31.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",58.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",64.3,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",69,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",59.5,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",67.9,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",53.4,"D","Difference in methodology"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",59.8,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",9.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",9.2,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.5,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",10.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",10.6,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",11.3,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10.9,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",11.4,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.7,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10.1,"D","Difference in methodology"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",17.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",18.6,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",18.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",20,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",21,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",22.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",24,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",26.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",27.1,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",31,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",31.8,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",32.5,"D","Difference in methodology"
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",37.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",10.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",10.9,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",11.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",12.3,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",13.1,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",14.2,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",15.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",16.4,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",16.8,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",17.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",17.7,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",17.5,"D","Difference in methodology"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",20.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",32.4,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",32.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",32.5,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",33.1,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",34,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",35.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",37.2,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",39.7,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",41.3,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",44.6,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",47.9,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",48,"D","Difference in methodology"
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",55.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",7,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",7.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",7.1,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",7.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",7.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",7.8,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",8.4,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",8.9,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",9.3,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",11.2,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",13.5,"D","Difference in methodology"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",17,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.3,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.8,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.9,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.1,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.4,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.7,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",2.6,"D","Difference in methodology"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",2.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.4,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.6,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",3.2,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.8,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",4.3,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",4.9,"D","Difference in methodology"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",5.1,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",2.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",2.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",2.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",2.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",2.3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",2.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",2.7,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",3,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",3.2,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",3.5,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",3.6,"D","Difference in methodology"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",4.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",20.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",20.9,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",21.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",23.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",24.2,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",24.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",27,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",29.4,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",30.5,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",32.1,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",29.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",29.7,"D","Difference in methodology"
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",45.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2010","2010",8.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2011","2011",8.7,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2012","2012",8.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2013","2013",9.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2014","2014",9.6,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2015","2015",9.3,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2016","2016",9.8,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2017","2017",10.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2018","2018",10,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2019","2019",10.4,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2020","2020",10.5,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2021","2021",10,"D","Difference in methodology"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","LVA","Latvia","2022","2022",11.2,"D","Difference in methodology"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.6,"B","Break"
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.5,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break"
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break"
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.3,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",2.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.7,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",3.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",3.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",3.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",3.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break"
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.4,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.4,"B","Break"
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.2,"B","Break"
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",11.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",9.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",8.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",8.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",10,"B","Break"
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",10.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",11.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",11.6,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",12.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",13.4,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",13.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",14.3,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",12.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",2.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",2.2,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",2.5,"B","Break"
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0,"B","Break"
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.4,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.5,"B","Break"
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",7.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",7.7,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",7.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",11,"B","Break"
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",9.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",9.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",9.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",10.5,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",12.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",9.6,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",11.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",10.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1.1,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.7,"B","Break"
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.7,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1.7,"B","Break"
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.8,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",2.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.8,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",2.2,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.9,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.4,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break"
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break"
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.1,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.2,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.3,"B","Break"
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",3.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",4,"B","Break"
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",3.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",3.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",4.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",5.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",5.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",5.7,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",4.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",1.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",1,"B","Break"
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",1.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",1.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",1.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",1.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",1.8,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",4.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",3.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",3.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",3.4,"B","Break"
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",2.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",2.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",2.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",2.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",1.8,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",2.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",1.7,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2010","2010",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2011","2011",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2012","2012",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2013","2013",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2014","2014",0.1,"B","Break"
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2015","2015",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2016","2016",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2017","2017",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2018","2018",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2019","2019",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2020","2020",0.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2021","2021",0.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","CRI","Costa Rica","2022","2022",0.1,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",83.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",91.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",101.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",105.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",110.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",116.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",120.7,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",122.9,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",128.5,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",133,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",130,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",120.9,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",135.8,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",142.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",152.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",181,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",238.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",272.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",287,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",356.2,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",396.1,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",456,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",4.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",4.2,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",3.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",4.5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",5,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",5.1,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",5.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",4.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",5.6,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",5.8,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",5.9,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",4.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",8.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",8.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",8.2,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",8.9,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",8.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",8.5,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",8.8,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",8.3,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",8.1,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",7.7,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",7.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",10.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",11.3,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",12.5,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",14.4,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",15.1,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",15.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",17.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",19.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",20.6,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",20.2,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",18.8,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",24,,
"PATCOTHR","Products not elsewhere classified","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",143.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",1.4,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",2.2,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",41.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",44.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",46.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",46.6,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",45.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",45.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",47.7,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.1,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",52.4,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",55.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",27.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",32.8,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",36.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",44.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",49.4,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",56.1,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",62.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",65.6,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",66.3,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",67.7,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",70.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",32,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",117.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",119,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",111,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",74.3,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.6,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",78.5,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",81.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",86.2,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",91.1,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",97.7,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",101.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",154.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",164.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",172.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",161.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",162.1,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",174.6,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",172.9,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",171.3,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",176.4,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",190.7,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",198.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",17.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",19.2,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",20.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",21.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",22.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",24.5,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",27.8,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",29.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",30.6,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",32.3,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",37.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",83.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",60.5,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",15.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.2,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",28.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",28.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",30.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",30.7,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",30.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",32.1,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",32.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",34,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",35.6,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",37.5,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",35.3,,
"PATCSHMG","G03-Sex hormones and modulators of the genital system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",36.9,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",128.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",135.5,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",141.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",146.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",144.6,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",151.4,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",160.7,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",171.2,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",166.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",157.3,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",157.1,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",178.7,,
"PATCDIUR","C03-Diuretics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",354.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",380.2,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",393,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",401.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",399,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",413.9,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",453.3,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",457.7,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",478.4,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",510,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",543.8,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",544.5,,
"PATCARAS","C09-Agents acting on the Renin-Angiotensin system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",12.3,,
"PATCACID","A02A-Antacids","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0,,
"PATCBIOT","J01-Antibacterials for systemic use","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",14.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",73.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",77.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",78.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",79.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",80.3,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",84.1,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",91.8,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",98.2,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",103.5,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",113,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",115.9,,
"PATCGENU","G-Genito urinary system and sex hormones","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",117.1,,
"PATCCNSY","N-Nervous system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",36.7,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",215.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",217.1,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",206.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",212.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",204.8,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",209.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",260,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",334.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",336,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",411.5,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",420.2,,
"PATCINFC","J-Antiinfectives for systemic use","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",809.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",152.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",156.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",155.6,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",164.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",162.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",177.4,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",192.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",196.5,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",214.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",243.2,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",240.1,,
"PATCRESS","R-Respiratory system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",242.7,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",289.8,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",323.5,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",341,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",353.2,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",347.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",367,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",413.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",438.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",458.9,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",512.3,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",524.4,,
"PATCALIM","A-Alimentary tract and metabolism","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",537,,
"PATCBLOO","B-Blood and blood forming organs","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",30.2,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",109.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",121.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",133.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",149.6,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",159.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",175.4,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",206.1,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",223.9,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",230.8,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",249,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",269.5,,
"PATCDIAB","A10-Drugs used in diabetes","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",282.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",50.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",51.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",54.4,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",58.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",65.8,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",70.5,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",76.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",84.6,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",93.9,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",98.3,,
"PATCFLAM","M01A-Antiinflammatory and antirheumatic products non-steroids","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",77.9,,
"PATCHYPN","N05C-Hypnotics and sedatives","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
"PATCARIT","C01B-Antiarrhythmics, Class I and III","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",0.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",38.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",42.9,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",43.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",45.2,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",46.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",49.1,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",49.4,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",50.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",53.6,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",55.3,,
"PATCANXO","N05B-Anxiolytics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",54.5,,
"PATCBETA","C07-Beta blocking agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",4.6,,
"PATCOBAI","R03-Drugs for obstructive airway diseases","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",8.6,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2.3,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",1.9,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2.4,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2.5,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2.5,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",2.7,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",2.7,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",2.8,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",2.9,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",2.4,,
"PATCGLYC","C01A-Cardiac glycosides","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",1.8,,
"PATCCHLS","C10-Lipid modifying agents","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",7.9,,
"PATCHORM","H-Systemic hormonal preparations, excluding sex hormones and insulins","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",2189.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",2375.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",2444.5,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",2567.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",2512.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",2685,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",3098.4,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",3364.9,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",3685.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",4408.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",4948.7,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",5785.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",95.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",97.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",98.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",103,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",99.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",104,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",115.9,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",125.1,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",179.7,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",208,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",199.5,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",181.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",89.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",93.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",96.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",80.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",63.2,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",58.1,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",59.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",63.7,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",67.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",73.8,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",70.6,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",76.1,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",84.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",90.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",92,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",93.6,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",92.9,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",95.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",98.2,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",100.4,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",110.7,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",124.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",139.5,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",138.8,,
"PATCTOTT","Total pharmaceutical sales","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",40153.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",66.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",68,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",66,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",60.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",57.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",52,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",52.3,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",45.5,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",39.2,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",37.1,,
"PATCCCBR","C08-Calcium channel blockers","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",33.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",39.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",40.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",41.4,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",41.6,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",41.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",41.3,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",43.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",43.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",43.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",43.8,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",45.9,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",46.9,,
"PATCPEPT","A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD)","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",5.3,,
"PATCSKEL","M-Musculo-skeletal system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",11.3,,
"PATCANAL","N02-Analgesics","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",42.2,,
"PATCDEPR","N06A-Antidepressants","PPPPERMT","/capita, US$ purchasing power parity","ROU","Romania","2022","2022",3.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",19.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",22.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",24.6,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",26.3,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",26.1,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",25,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",23,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",25.8,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",29.5,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",34,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",42.4,,
"PATCHYPO","C02-Antihypertensives","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",42.2,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2010","2010",441.4,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2011","2011",461.3,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2012","2012",484.1,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2013","2013",468.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2014","2014",390.5,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2015","2015",398.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2016","2016",414.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2017","2017",430.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2018","2018",440.6,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2019","2019",470.8,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2020","2020",507.9,,
"PATCCARV","C-Cardiovascular system","PPPPERMT","/capita, US$ purchasing power parity","HRV","Croatia","2021","2021",515.5,,
